Omnicell, Inc. (NASDAQ:OMCL) Shares Acquired by Dimensional Fund Advisors LP

Dimensional Fund Advisors LP boosted its stake in Omnicell, Inc. (NASDAQ:OMCLFree Report) by 2.1% in the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 1,067,516 shares of the company’s stock after purchasing an additional 21,798 shares during the period. Dimensional Fund Advisors LP owned approximately 2.35% of Omnicell worth $40,173,000 at the end of the most recent reporting period.

Several other hedge funds also recently added to or reduced their stakes in OMCL. Charles Schwab Investment Management Inc. raised its holdings in shares of Omnicell by 7.2% during the 4th quarter. Charles Schwab Investment Management Inc. now owns 483,443 shares of the company’s stock valued at $18,192,000 after buying an additional 32,548 shares during the period. M&T Bank Corp lifted its holdings in Omnicell by 16.0% in the 4th quarter. M&T Bank Corp now owns 9,570 shares of the company’s stock worth $360,000 after buying an additional 1,321 shares in the last quarter. Summit Global Investments grew its stake in shares of Omnicell by 24.9% during the fourth quarter. Summit Global Investments now owns 20,855 shares of the company’s stock valued at $785,000 after acquiring an additional 4,158 shares in the last quarter. Victory Capital Management Inc. grew its stake in shares of Omnicell by 465.1% during the fourth quarter. Victory Capital Management Inc. now owns 44,766 shares of the company’s stock valued at $1,685,000 after acquiring an additional 36,844 shares in the last quarter. Finally, Avory & Company LLC lifted its stake in shares of Omnicell by 25.6% in the fourth quarter. Avory & Company LLC now owns 193,162 shares of the company’s stock worth $7,269,000 after acquiring an additional 39,386 shares in the last quarter. 97.70% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

Several equities research analysts have issued reports on the company. Wells Fargo & Company dropped their price objective on Omnicell from $28.00 to $26.00 and set an “equal weight” rating on the stock in a report on Friday, February 9th. Benchmark reaffirmed a “buy” rating and issued a $38.00 price target on shares of Omnicell in a report on Tuesday, April 30th. One equities research analyst has rated the stock with a sell rating, three have given a hold rating and three have given a buy rating to the company. According to MarketBeat, the company has an average rating of “Hold” and a consensus target price of $42.20.

Check Out Our Latest Analysis on Omnicell

Omnicell Stock Performance

Omnicell stock opened at $32.65 on Friday. The company has a debt-to-equity ratio of 0.48, a current ratio of 2.38 and a quick ratio of 2.13. Omnicell, Inc. has a 12 month low of $25.69 and a 12 month high of $77.14. The company has a fifty day moving average price of $29.13 and a two-hundred day moving average price of $31.31. The company has a market cap of $1.50 billion, a PE ratio of -70.98, a P/E/G ratio of 116.84 and a beta of 0.77.

Omnicell (NASDAQ:OMCLGet Free Report) last posted its quarterly earnings results on Thursday, May 2nd. The company reported ($0.14) EPS for the quarter, beating the consensus estimate of ($0.31) by $0.17. The business had revenue of $246.15 million during the quarter, compared to analyst estimates of $235.70 million. Omnicell had a negative net margin of 1.91% and a positive return on equity of 2.41%. Research analysts expect that Omnicell, Inc. will post 0.2 earnings per share for the current year.

About Omnicell

(Free Report)

Omnicell, Inc, together with its subsidiaries, provides medication management solutions and adherence tools for healthcare systems and pharmacies the United States and internationally. The company offers point of care automation solutions to improve clinician workflows in patient care areas of the healthcare system; XT Series automated dispensing systems for medications and supplies used in nursing units and other clinical areas of the hospital, as well as specialized automated dispensing systems for operating room; and robotic dispensing systems for handling the stocking and retrieval of boxed medications.

Recommended Stories

Institutional Ownership by Quarter for Omnicell (NASDAQ:OMCL)

Receive News & Ratings for Omnicell Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Omnicell and related companies with MarketBeat.com's FREE daily email newsletter.